Adverum Biotechnologies, Inc.ADVM was a big mover last session, as the company saw its shares rise nearly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $3.15 to $3.90 in the past one-month time frame.
The company has not seen any change when it comes to estimate revision over the past few months, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Adverum Biotechnologies currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Adverum Biotechnologies, Inc. Price
Adverum Biotechnologies, Inc. Price | Adverum Biotechnologies, Inc. Quote
A better-ranked stock in the Medical sector is Aduro BioTech, Inc. ADRO, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ADVM going up? Or down? Predict to see what others think: Up or Down
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aduro Biotech, Inc. (ADRO) : Free Stock Analysis Report
Adverum Biotechnologies, Inc. (ADVM) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research